Multiple Myeloma – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Powered by
Access in-depth insight and stay ahead of the market
Explore in-depth market insights from the following data in our ‘Multiple Myeloma Cell Therapy Market’ report:
- Access updated epidemiology for patient populations relevant to cell therapy in 2021-2031
- Review updated prescription habits at the class level for already established therapies (defined in our analysis as chemotherapy, targeted therapies, and others [such as immune checkpoint inhibitors or hormone therapies]) and compare their future projections to cell therapy pipeline drugs
- Full market assessment in the 8MM of all currently marketed and late-stage pipeline cell therapy drugs with drug-level forecasts, supplemented by class-level forecasts for early-stage molecules
- Explore indication-specific top-line sales forecasts across 15 countries, in the 8MM and Australia, Belgium, Canada, Denmark, Israel, South Korea, and Switzerland, facilitating global R&D and investment strategies in countries that may be particularly promising for cell therapies
- Compare region-and indication-specific market shares for all prescribed classes of drugs in multiple myeloma to identify market size and potential outside the 8 major markets
How is the ‘Multiple Myeloma Cell Therapy Market’ report different from other reports in the market?
- Report deliverables include a PowerPoint report and an Excel-based forecast model
- Obtain cell therapy sales forecasts across multiple regions
- Gain insight into promising early-stage approaches
- Our indication-specific forecast models answer questions such as:
- What is the target patient pool for cell and gene therapies in each cancer indication?
- Which patient groups are more likely to receive these therapies?
- What does the cell & gene therapy clinical-stage pipeline look like in each cancer indication?
- What is the anticipated breakdown between autologous and allogeneic cell therapies?
- When will cell & gene therapies launch in each market?
- What is the total market value projected for the forecast end, in 2031?
We recommend this valuable source of information to anyone involved in:
- Pharmaceutical Industry (Big Pharma, Small Biotech, Start-ups, etc.),
- Pharmaceutical Industry Suppliers (e.g., Consulting Companies, CMOs, CDMOs, CROs, Technology Vendors)
- Professional Services (e.g., Investment Companies, Investment Banks, Equity Companies, etc.)
- Biotech Companies
Currently working in this field of expertise or those looking to enter this market as Executives working within the pharmaceutical industry or for the companies that provide services to pharmaceutical industry (CEOs, presidents, board of directors, managing directors, strategy and innovation, marketing and sales, market intelligence, business insights, product directors, investment directors, global venture partners, equity analysts, management and lifescience consultants.
To get a snapshot of the multiple myeloma cell therapy market report, download a free report sample
Multiple Myeloma Cell Therapy Market Overview
The Multiple Myeloma (MM) market value for the 15 markets (15M) was $25.7 billion in 2021. This included both cell therapies and established/traditional MM therapies. The 15 markets comprise the 8MM and seven countries known to have increased potential for cell therapies given the current drug development landscape, namely Australia, South Korea, Belgium, Denmark, Switzerland, Israel, and Canada.
The Multiple Myeloma Cell Therapy market research report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the eight major markets (8MM) for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late clinical stage pipeline products, with a launch date assessment by market for multiple myeloma.
Multiple Myeloma Cell Therapy Market Drivers and Unmet Needs
Established CAR-T agents such as Abecma and Carvykti are expected to grow their market share via label expansions into earlier lines of therapy.
Personalized treatment approaches and heavily pre-treated patients are some of the unmet needs of the Multiple Myeloma Cell Therapy market. Abecma and Carvykti have provided therapeutic options for patients in later-line settings. The launch of Carvykti in China for use in 3L+ settings will address such unmet needs. These marketed CAR-T cell therapies aim to move into earlier lines of therapy.
To know more about the Multiple Myeloma Cell Therapy market drivers, download a free report sample
MM Market Segmentation by Regions
The key regions in the Multiple Myeloma Cell Therapy market are North America, APAC, Europe, and the Middle East. North America had the highest share in 2021.
Multiple Myeloma Cell Therapy Market Analysis by Regions,2021 (%)
For more regional insights on the Multiple Myeloma market, download a free report sample
Multiple Myeloma Cell Therapy Market - Competitive Landscape
Some of the future players in the Multiple Myeloma Cell Therapy market are Celgene Corp, Johnson & Johnson, Chongqing Precision Biotech Co ltd, Shangai Changzheng Hospital, and MediGene AG, among others. Celgene Corp has the highest number of products in ongoing clinical trials and development phases. Leading Multiple Myeloma Cell Therapy players, such as Johnson & Johnson and Bristol Myers Squibb, are all looking to bolster their positions as market leaders by entering their cell therapies into trials for earlier-stage settings.
Multiple Myeloma Cell Therapy Market Report Overview
Market Size (2021 in 15M) | $25.7 billion |
Key Regions | North America, APAC, Europe, and The Middle East |
Future Players | Celgene Corp, Johnson & Johnson, Chongqing Precision Biotech Co ltd, Shangai Changzheng Hospital, and MediGene AG, among others |
Key Players
BMSJ&J
Nanjing IASO Biotherapeutics
Arcellx
CARsgen Therapeutics
Table of Contents
Frequently asked questions
-
What was the Multiple Myeloma Cell Therapy market size in the 15M in 2021?
The Multiple Myeloma Cell Therapy market value for the 15 markets (15M) was $25.7 billion in 2021.
-
Which are the key regions in the Multiple Myeloma Cell Therapy market?
The key regions in the Multiple Myeloma Cell Therapy market are North America, APAC, Europe, and the Middle East.
-
Which region had the highest share in the Multiple Myeloma Cell Therapy market?
North America had the highest share of the Multiple Myeloma Cell Therapy market.
-
Who are the future players in the Multiple Myeloma Cell Therapy market?
Some of the future players in the MM market are Celgene Corp, Johnson & Johnson, Chongqing Precision Biotech Co ltd, Shangai Changzheng Hospital, and MediGene AG, among others.
-
Which player has the highest number of products in the Multiple Myeloma Cell Therapy market?
Celgene Corp has the highest number of products in ongoing clinical trials and development phases.
-
How are leading players trying to bolster their positions as leaders in the Multiple Myeloma Cell Therapy market?
Leading Multiple Myeloma Cell Therapy players, such as Johnson & Johnson and Bristol Myers Squibb, are all looking to bolster their positions as market leaders by entering their cell therapies into trials for earlier-stage settings.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.